title: New drugs for peripheral joint psoriatic arthritis.
abstract: Up to 3% of people have psoriasis, and as many as 42% of these have an associated chronic inflammatory arthritis. In up to 20% of such patients, the arthritis progresses to become severe, destructive and deforming. Traditional drug treatments include NSAIDs and disease-modifying anti-rheumatic drugs (DMARDs) used for rheumatoid arthritis. Leflunomide (Arava - Sanofi-Aventis), etanercept (Enbrel - Wyeth) inifliximab (Remicade - Schering-Plough) and adalimumab (Humira - Abbott) are licensed for the treatment of patients with peripheral joint disease in psoriatic arthritis. Here we review drug therapy for such patients, concentrating on the newer agents.
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents